Neoadjuvant Fruquintinib Plus Tislelizumab Combined With mCapeOX Versus CapeOX for Mid-high pMMR/MSS Locally Advanced Rectal Cancer

NCT06443671 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

NOT_YET_RECRUITING

Status

132

Enrollment

OTHER

Sponsor class

Conditions

Rectal Cancer

Interventions

DRUG: CapeOX
DRUG: Fruquintinib and Tislelizumab combined with mCapeOX

Sponsor

Peking University Cancer Hospital & Institute